{
  "id": 5314514,
  "title": "Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference",
  "url": "https://urgent.news/2026/09/03/medicenna-to-present-at-the-h-c-wainwright-28th-annual-global",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T11:03:03.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/medicenna-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference"
  },
  "original_language": "en",
  "account": null,
  "summary": "TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}